retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity for weight loss: Study shows 30% body weight loss Retatrutide just made bariatric surgery

February/April 2010

These metabolic differences are generally modest compared to the dramatic difference in total weight loss

When a new prescription drug enters the market, the question for employers isnt just does it work? Its what does covering it mean for our people, our plan, and our longterm costs? That question became especially relevant in early 2026, when an oral version of Wegovy entered the market with widespread media coverage

More research is needed to understand the mechanism fully and determine how common this side effect may be

Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice

The CT values of all the groups for expression of each gene of interest were normalized to their respective -actin values and were presented as relative fold change of gene expression as compared to the control group